Related Experiment Video
Updated: Jun 23, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
Cannabinoids in intestinal inflammation and cancer
Angelo A Izzo1, Michael Camilleri
1Department of Experimental Pharmacology, University of Naples Federico II and Endocannabinoid Research Group, Naples, Italy. aaizzo@unina.it
Cannabinoids show promise for treating intestinal inflammation and colon cancer by reducing cell proliferation and promoting healing. Modulating the endocannabinoid system may offer a new therapeutic strategy for these conditions.
Area of Science:
- Gastroenterology
- Oncology
- Pharmacology
Background:
- The endocannabinoid system (ECS) is altered in inflammatory bowel disease (IBD) and colon cancer patients.
- Cannabinoids demonstrate antiproliferative, antimetastatic, and apoptotic effects on intestinal epithelial cells.
- Cannabinoids reduce cytokine release and enhance wound healing in cellular studies.
Purpose of the Study:
- To review the evidence for cannabinoids' effects on intestinal inflammation and cancer.
- To explore the role of the endocannabinoid system in these gastrointestinal diseases.
Main Methods:
- Review of preclinical studies on cannabinoids in intestinal inflammation and colon cancer models.
- Analysis of research on cannabinoid receptor (CB1 and CB2) activation.
- Examination of adaptive changes in the ECS in patient biopsies.
Main Results:
- Cannabinoids exert protective effects in established models of intestinal inflammation and colon cancer.
- Activation of CB1 and/or CB2 receptors mediates these protective effects.
- Pharmacological enhancement of endocannabinoid levels shows therapeutic potential.
Conclusions:
- Cannabinoids possess therapeutic potential for managing intestinal inflammation and colon cancer.
- Targeting the endocannabinoid system presents a promising strategy for gastrointestinal disease treatment.
More Related Videos
09:04DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Two synthetic agonists of THC,...
Inflammatory Bowel Disease III: Crohn's Disease
Inflammatory Bowel Disease II: Ulcerative Colitis
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease I: Introduction